Biotech News
Leyden Labs Secures €20M from EIB to Advance Nasal Spray Against Influenza
Dutch clinical-stage biotechnology company Leyden Laboratories B.V. has secured €20 million in financing from the European Investment Bank (EIB) to accelerate the development of its pan-influenza nasal spray and other antibody-based respiratory therapies. The funding aims to bolster Europe’s readiness against seasonal
4 June 2025